U.S. Markets closed

Looking Into Emergent BioSolutions's Return On Capital Employed

·1 min read

Looking at Q4, Emergent BioSolutions (NYSE:EBS) earned $258.10 million, a 321.04% increase from the preceding quarter. Emergent BioSolutions also posted a total of $583.00 million in sales, a 51.35% increase since Q3. Emergent BioSolutions earned $61.30 million, and sales totaled $385.20 million in Q3.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q4, Emergent BioSolutions posted an ROCE of 0.18%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

View more earnings on EBS

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

In Emergent BioSolutions's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.

Q4 Earnings Recap

Emergent BioSolutions reported Q4 earnings per share at $3.67/share, which beat analyst predictions of $3.19/share.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.